Patients and methods—One hundred and seventy eight patients were randomised to receive budesonide controlled ileal release (CIR) capsules 9 mg once daily or 4.5 mg twice daily, or prednisolone tablets ...
NANJING, China, February 20, 2025--(BUSINESS WIRE)--Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN) has achieved positive ...
Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN) has achieved positive results in recent clinical study. D23 is budesonide ...
a Department of Paediatrics, Kolding Hospital, DK-6000 Kolding, Denmark, b Astra Draco AB, PO Box 34, S-221 00, Lund, Sweden AIM To evaluate the systemic availability and basic pharmacokinetic ...
BACKGROUND Steroid dependent patients with Crohn's disease are at high risk of developing glucocorticosteroid induced side effects. AIMS We evaluated the possibility ...
AIMS To determine whether nebulised budesonide improves the symptoms or shortens the duration of stay of children admitted to hospital with a clinical diagnosis of croup. METHODS A prospective, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results